AB0619 Isotypes of Anti-Beta 2- Glycoprotein I in Systemic Lupus Erythematosus Patients: Correlation with Clinical Manifestations, Laboratory Features and Association with Antiphospholipid Syndrome

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 1106.2-1106
Author(s):  
D. Attia ◽  
T.A. Gheita ◽  
A. El Awar ◽  
A. Abd Alaal ◽  
M. Ayoub
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Clinical Manifestations ◽  
Systemic Lupus ◽  
Glycoprotein I ◽  
Laboratory Features ◽  
Beta 2

scholarly journals Screening Tests of Reproductive Immunology in Systemic Lupus Erythematosus

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Zdenka Ulcova-Gallova ◽  
Alice Mockova ◽  
Miroslava Cedikova
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Phosphatidyl Ethanolamine ◽  
Phosphatidyl Inositol ◽  
Phosphatidyl Serine ◽  
Sperm Cells ◽  
Systemic Lupus ◽  
Ethanolamine Phosphatidyl ◽  
Glycoprotein I ◽  
Beta 2

Female patients in reproductive age with systemic lupus erythematosus and fertility complications together are observed by rheumatologists, gynecologists, and reproductive immunologists. The paper notes the presence of autoantibodies to zona pellucida, to phospholipids (phosphatidyl serine, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl glycerol, phosphatidic acid, annexin V, beta-2 glycoprotein I, and cardiolipin) and of isoantibodies to sperm cells. Isoantibodies to sperm cells are not significantly predominant, but autoimmunity is well expressed in IgG positivity against phosphatidyl inositol, phosphatidyl ethanolamine, phosphatidyl serine, cardiolipin, and beta-2 glycoprotein I, as well as antizona pellucida antibodies in IgG isotype. According to the levels of autoantibodies we have to choose preventive treatment to protect mother and her foetus.

Anti-beta-2 glycoprotein I antibodies in patients with Systemic Lupus Erythematosus and Systemic Sclerosis — Clinical significance

1997 ◽  
Vol 56 ◽  
pp. 475-476
Author(s):  
M.E.A. Evangelopoulos ◽  
D.A. Sotos ◽  
A. Levedakos ◽  
M.E. Mavrikakis ◽  
C.D. Evangelopoulos
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Systemic Sclerosis ◽  
Clinical Significance ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Glycoprotein I ◽  
Beta 2

Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus

2004 ◽  
Vol 92 (12) ◽  
pp. 1303-1311 ◽  
Author(s):  
Anthi Balitsari ◽  
John Routsias ◽  
Panayiotis G.Vlachoyiannopoulos ◽  
Clio Mavragani ◽  
Efi Bourazopoulou
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Amino Acid Position ◽  
Systemic Lupus ◽  
Multiple Antigenic Peptide ◽  
Glycoprotein I ◽  
Peptide Carrier ◽  
Intracellular Domains ◽  
Peptide Antibodies

SummaryAnti-β2glycoprotein I (anti-β2GPI) antibodies constitute the main autoantibody specificity in the sera of patients with antiphospholipid syndrome (APS). There is evidence that antiβ2GPI antibodies induce the precoagulant activity of the endothelium by cross-linking the β2 glycoprotein I (β2GPI) on the cell surface. Since β2GPI lacks intracellular domains, homology with other molecules such as CD40 that could initiate signaling, was extensively searched. A 86% homology between the amino acid position 239-245 of the CD40 and 7-13 of the β2glycoprotein was found. The CD40 peptide corresponding to amino acids 239-245 of the CD40 molecule was synthesized and coupled to a multiple antigenic peptide carrier. Antibodies to CD40 peptide were found in 61.5% APS patients (n=39), in 72.7% of systemic lupus erythematosus (SLE) positive for anti β2GPI antibodies (n=11) and 31.6% of SLE negative for antiβ2GPI antibodies (n=19), but not in rheumatoid arthritis patients (n=28) or controls (n=36). Antibodies to CD40 peptide were associated with arterial thrombosis and/or brain microinfarcts. Affinity purified anti-CD40 peptide antibodies as well as affinity purified anti-β2GPI antibodies recognized both, the β2GPI and the CD40 peptide. The specificity of this recognition was confirmed with homologous and heterologous inhibition experiments. Confocal microscopy experiments demonstrated this cross-recognition of CD40 and β2GPI molecules, by the purified anti-CD40 peptide antibodies, at the protein level. Thus, antibodies reacting with the β2GPI can react and potentially activate different cells which express CD40 molecules at their surface.

IgM Anti-ß2Glycoprotein I Is Protective Against Lupus Nephritis and Renal Damage in Systemic Lupus Erythematosus

2010 ◽  
Vol 38 (3) ◽  
pp. 450-453 ◽  
Author(s):  
TARANEH MEHRANI ◽  
MICHELLE PETRI
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Nephritis ◽  
Protective Effect ◽  
Lupus Erythematosus ◽  
Renal Damage ◽  
Damage Index ◽  
Clinical Manifestations ◽  
Systemic Lupus ◽  
American College Of Rheumatology ◽  
Glycoprotein I

Objective.Antibodies to ß2glycoprotein I (IgG and IgM isotypes) have recently been added to the laboratory criteria of the revised antiphospholipid syndrome classification criteria. We investigated whether IgM anti-ß2-glycoprotein I (anti-ß2-GPI) is associated with clinical manifestations of systemic lupus erythematosus (SLE).Methods.Anti-ß2-GPI was measured in 796 patients with SLE (93% women, 53% white, 38% African American, mean age 45 yrs). IgM anti-ß2-GPI (> 20 phospholipid units) was found in 16%. Associations were determined with clinical manifestations of SLE and with components of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.Results.As expected, IgM anti-ß2-GPI was highly associated with both the lupus anticoagulant and with anticardiolipin. It was associated with transient ischemic attack (OR 2.64, p = 0.04), but not significantly with venous or arterial thrombosis. IgM anti-ß2-GPI was protective against lupus nephritis (OR 0.54, p = 0.049), renal damage (p = 0.019), and hypertension (OR 0.58, p = 0.008). This protective effect remained after adjustment for ethnicity.Conclusion.In SLE, IgM anti-ß2-GPI is not associated with thrombosis but is protective against lupus nephritis and renal damage. “Natural” autoantibodies of the IgM isotype may have a protective effect.

Sign in / Sign up

Export Citation Format

Share Document